parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.05 from other evidence	0.00
cell type Human Protein Atlas	group enriched in oligodendrocytes (158 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	4 Parkinson's papers of 149	0.79
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 5523

ELAVL3 in dopamine neurons, braak-0.37 (p 0.323) → +0.16 (p 0.685)receipt 5531
ELAVL3 in oligodendrocytes, braak-0.77 (p 0.016) → +0.11 (p 0.785)receipt 5530

receipt 5531: ELAVL3 in dopamine neurons, braak

power: full sample -0.27 (p 0.285, n 18), 95% CI -0.65 to +0.23. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.30 (p 0.232, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.37 (p 0.130, n 18). could be the mix.
skeptic: leave-one-out range -0.38 to -0.16, sign flips 0; without severely affected donors -0.27 (p 0.285, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ELAVL3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 5530: ELAVL3 in oligodendrocytes, braak

power: full sample -0.54 (p 0.019, n 18), 95% CI -0.81 to -0.10. the interval excludes zero: something may be there, smaller than a half can see.
confounder: adjusted for sex: -0.58 (p 0.011, n 18). holds up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.59 (p 0.011, n 18). not the mix.
skeptic: leave-one-out range -0.72 to -0.48, sign flips 0; without severely affected donors -0.54 (p 0.019, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ELAVL3 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts